Tuberculous peritonitis after treatment with adalimumab

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 8, 2008, Pages 677-678

  Antolin, Jose ^a   Azahara, Marcos ^a   Hernandez, Clara ^a   Blanco, Margarita ^a   Mao, Laura ^a   Ciguenza, Ramon ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADENOSINE DEAMINASE; ISONIAZID; METHOTREXATE; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN;

ABDOMINAL PAIN; AGED; ARTICLE; ASCITES; ASCITES FLUID; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; LAPAROSCOPY; LIVER DYSFUNCTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARACENTESIS; RHEUMATOID ARTHRITIS; TUBERCULOUS PERITONITIS;

AGED; ANTIBIOTICS, ANTITUBERCULAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; PERITONITIS, TUBERCULOUS; PYRAZINAMIDE; RIFAMPIN;

EID: 48249141451     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701877320     Document Type: Article

References (14)

1. Manadan, AM, Block, JA and Sequeira, W. (2003) Mycobacteria tuberculosis peritonitis associated with etarnecept therapy. 21, p. 526.
2. Gutierrez-Macias, A., Lizarralde-Palacios, E., Martinez-Odriozola, P. and Miguel-de la Villa, F (2007) Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab. 26 pp. 452-453.
3. Toussirot, E., Streit, G and Wendling, D. (2007) Infectious complications with anti-TNFα. therapy in rheumatic diseases: A review. Recent patents on inflammation and allergy. 1, pp. 39-47.
4. Olsen, NJ and Stein, CM. (2004) New drugs for rheumatoid arthritis. 350, pp. 2167-2179.
5. Bieber, J. and Kavanaugh, A. (2004) Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biological treatments. 30, pp. 257-270.
6. Scheinfeld, N. (2005) Adalimumab: A review of side-effects. 4, pp. 637-641.
7. Keane, J., Gershon, S., Wise, RP, Mirabile-Levens, E., Kasznica, J. Schwieterman, WD et al. (2001) Tuberculosis associated with infliximab, a tumour necrosis factor a-neutralizing agent. 345, pp. 1098-1104.
8. Mohan, AK, Cote, TR, Block, JA, Manadan, AM, Siegel, JN and Braun, MM. (2004) Tuberculosis following the use of etarnecept, a tumour necrosis factor inhibitor. 39, pp. 295-299.
9. Wallis, RS, Broder, MS, Wong, JY, Hanson, ME and Beenouwer, DO. (2004) Granulomatous infectious diseases associated with tumour necrosis factor antagonists. 38, pp. 1261-1265.
10. Carmona, L., Hernandez-Garcia, C., Vadillo, C., Pato, E., Balsa, A., Gonzalez-Alvaro, I. and EMECAR Study Group (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. 30, pp. 1436-1439.
11. Ehlers, S. (2005) Tumour necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept?. 41, p. S199.
12. Kent, JD, Pangan, AL and Fitzpatrick, SB. (2005) Analysis of the US post-marketing safety of adalimumab (HUMIRA) in patients with rheumatoid arthritis during the first 2 y after approval. 52, p. S548.
13. Tubach, F., Salmon, D., Ravaud, P., Lortholary, O., Baldin, B. Bretagne, S. et al. (2005) Tuberculosis complicating TNF-alpha antagonist therapy in a prospective multicentre stud in France: A persistent risk despite preventive guidelines. 52:9, p. 851.
14. Sichletidis, L., Settas, L., Spyratos, D., Chloros, D. and Patakas, D. (2006) Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. 10, pp. 1127-1132.